Research
Hormonal
Tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.
Tirzepatide may be a promising treatment option for patients with MASH, potentially improving liver health.
StrongSupportsmedium confidence
Results from SYNERGY-NASH...have shown that tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.
Why this rating
Based on results from a phase 2 clinical trial.
Source
Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives
Stefano Fiorucci et al. · Expert Opinion on Investigational Drugs · 2025
rctCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →